RxDoctor Payments DataLook up a doctor →

Ahmed Zakari, MD

Hematology · Altamonte Springs, FLNPI 1447268297

Payments from drug & device makers

$1,303,211in general payments, 2019–2025

Across 601 payments — averaging $2168.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$435K
  • AbbVie$209K
  • AstraZeneca$188K
  • Incyte Corporation$160K
  • Bristol Myers Squibb$60K
  • Taiho Oncology, Inc.$56K
  • plus $195K from 38 others
$3,752in research payments, 2019–2025

Across 1 payment — averaging $3752.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bristol Myers Squibb$4K

What the payments were for

  • Consulting fees$37,71110%
  • Speaking & faculty fees$296,68877%
  • Travel & lodging$34,1809%
  • Food & beverage$14,1174%
  • Education$4850%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,303,211 in reported general payments places this provider in the 85th percentile of 79 hematology providers in Florida.

See all hematology providers in Florida

Medicare billing

Part B allowed, 2024
$274,627
Medicare patients
1,899
Services billed
17,794

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LonsurfTrifluridine/Tipiracil Hcl32$399,843
LenvimaLenvatinib Mesylate13$296,712
TasignaNilotinib Hcl12$226,068
CalquenceAcalabrutinib Maleate14$205,595
InqoviDecitabine/Cedazuridine12$96,009
Fentanyl44$3,939
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen75$2,031
Oxycodone Hcl96$1,953
Ondansetron OdtOndansetron58$1,783
Morphine Sulfate ErMorphine Sulfate39$1,171
CholestyramineCholestyramine (With Sugar)11$1,030
Tramadol Hcl87$968
Ondansetron Hcl27$963
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen33$810
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine31$736

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Taiho Oncology, Inc.Lonsurf, Inqovi$55,936$495,85244 claims
Eisai Inc.Lenvima$123$296,71213 claims
NovartisTasigna$3,606$226,06812 claims
AstraZenecaCalquence$188,055$205,59514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 79 hematology providers in Florida.

Other hematology in Altamonte Springs

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →